EU/3/06/404

Table of contents

About

On 23 October 2006, orphan designation (EU/3/06/404) was granted by the European Commission to Gendux AB, Sweden, for adenoviral vector containing human p53 gene for the treatment of Li-Fraumeni syndrome.

The sponsorship was transferred to Gendux Molecular Limited, Ireland, in December 2007.

Key facts

Active substance
Adenoviral vector containing human p53 gene
Disease / condition
Treatment of Li Fraumeni Syndrome
Date of first decision
23/10/2006
Outcome
Positive
EU designation number
EU/3/06/404

Sponsor's contact details

Gendux Molecular Limited
70 Sir John Rogerson’s Quay
Dublin 2
Ireland
Telephone: +353 1 849 1400
Telefax: +353 1 849 1401
E-mail: info@gendux.ie

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating